BiologicalDrug
Hepatitis B Surface Antigens clinical trials
Keep track of what changes. Save the Hepatitis B Surface Antigens studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
6 studies that test it; most in 2013 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 6
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Rockefeller University (2) · Vaxine Pty Ltd (1) · GlaxoSmithKline (1) · Immutep S.A.S. (1) · Eunice Dube (1) · Assiut University (1)
Often tested with
Tested in the same studies.
Hepatitis B Vaccines (4) · AIDS Vaccines (2) · Hepatitis B Antigens (1) · Etilagimod alpha (1)
Studies
Open first, then newest update. How each study uses Hepatitis B Surface Antigens is read from its arms, and is right about nine times in ten.
Testing it · 9
- Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.Not yet recruitingPhase 4Eunice DubeNCT06786429Written as Hepatitis B Virus Vaccine(HBV)
- Evaluation of the Efficacy of Cryotherapy Combined With Intralesional Hepatitis B Virus Vaccine Versus Either Therapy in the Treatment of Multiple Cutaneous Warts :a Comparative StudyNot yet recruitingEarly Phase 1Assiut UniversityNCT05902624Written as Hepatitis B Virus Vaccine(HBV)
- HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal CentersTerminatedPhase 4Rockefeller UniversityNCT05272735Written as Hepatitis B Vaccine (Recombinant)
- A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000745Written as Hepatitis B Vaccine (Recombinant)
- A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive IndividualsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000633Written as Hepatitis B Vaccine (Recombinant)
- Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B VaccineCompletedPhase 1Vaxine Pty LtdNCT01951677Written as HBsAg
- Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant SystemCompletedPhase 2GlaxoSmithKlineNCT01777295Written as Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.
- Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy VolunteersCompletedNot applicableRockefeller UniversityNCT02055365Written as Hepatitis B Vaccine (Recombinant)
- A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321CompletedPhase 1Immutep S.A.S.NCT00354861Written as hepatitis B antigen (without alum) plus IMP321
Given in every arm · 2 — Hepatitis B Surface Antigens is usual care beside what is tested
- Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine RegimenStatus unknownPhase 2Central Hospital, Nancy, FranceNCT05028322Written as HEPATITIS B SURFACE ANTIGEN
- Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B VaccineCompletedPhase 2GlaxoSmithKlineNCT00805389Written as HBsAg (Booster injection)
As the comparator · 4 — what is tested is compared with Hepatitis B Surface Antigens
- Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected IndividualsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00272493Written as Hepatitis B virus vaccine
- A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03110757Written as Hepatitis B Virus Vaccine (Recombinant)
- Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure PatientsCompletedPhase 1Dynavax Technologies CorporationNCT00426712Written as Hepatitis B Vaccine (Recombinant)
- A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)CompletedPhase 3Merck Sharp & Dohme LLCNCT00414050Written as Hepatitis B Vaccine (Recombinant)
Codes
What other systems call Hepatitis B Surface Antigens · ClinicalTrials.gg INT007607
- RxNorm 797752One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| RxNorm | 797752 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.